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tivecommons.org/licenses/by-nc-Summary Gallbladder sarcomatoid carcinoma is a rare neoplasm characterized by the simul-
taneous presence of malignant epithelial and mesenchymal components. There is little infor-
mation about the clinical behavior and optimal treatment for these tumors. The current study
examines the case of a 52-year-old female patient who presented with postprandial epigastric
pain that had persisted for 1 year. A diagnosis of gallbladder sarcomatoid carcinoma was
confirmed by pathology after radical resection. Peritoneal metastasis occurred 3 months later,
and the patient died 6 months after diagnosis. This study found that the prognosis of gall-
bladder sarcomatoid carcinoma is poor even after curative resection and there is as yet no
known effective adjuvant therapy.
Copyright ª 2015, The Gastroenterological Society of Taiwan, The Digestive Endoscopy Society
of Taiwan and Taiwan Association for the Study of the Liver. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Adenocarcinoma is the most common type of malignant
tumor generated in the gallbladder, whereas sarcomatoidf Gastroenterology, Depart-
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nd/4.0/).carcinoma (also called carcinosarcoma) is rare [1]. The
diagnosis of sarcomatoid carcinoma is generally made
pathologically and requires the simultaneous presence of
both malignant epithelial and mesenchymal components.
Immunohistochemically, the epithelial component is posi-
tive for cytokeratin and the mesenchymal component is
positive for vimentin [2]. In a meta-analysis of sarcomatoid
carcinoma, adenocarcinoma was found to be the most
common pathology in the epithelial component, followed, The Digestive Endoscopy Society of Taiwan and Taiwan Association
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Figure 1 Abdominal ultrasonography showing one mixed
echogenic tumor approximately 9.5 cm from the head of the
gallbladder sac. The common bile duct was dilated to 1.4 cm.
62 M.-W. Wong et al.by mixed adenosquamous cell carcinoma and squamous cell
carcinoma. In the mesenchymal component, spindle cell
pathology occurred most frequently followed by combined
spindle cell and chondroid features, and osteoid histology
[3].
Sarcomatoid carcinoma of the gallbladder was first re-
ported in 1907 by Landsteiner [4]. Since then, less than 100
further cases have been reported in the English literature
[1]. Like gallbladder adenocarcinoma, gallbladder sarco-
matoid carcinoma is most common in women. The female/
male ratio is between 3.25:1 and 5:1 [1,3]. The age at
diagnosis ranges from 45 to 91 years old [3]. Sarcomatoid
carcinoma is rare at sites such as the lungs, kidneys,
gastrointestinal tract and gallbladder, and occurs more
commonly in the uterus where it is known as a malignant
mixed Mu¨llerian tumor [5].
Case report
A 52-year-old female patient presented with postprandial
epigastric pain that had persisted for 1 year. The pain was
mild and improved after antacid treatment. She was seen
at our hospital after being diagnosed with a hepatic tumor
at a local clinic. Abdominal ultrasonography revealed one
mixed echogenic tumor approximately 9.5 cm from the
gallbladder sac and extending to S4e5 of the liver. The
common bile duct was dilated to 1.4 cm (Fig. 1). Liver
function tests and total bilirubin levels were within the
normal range. However, carbohydrate antigen 19-9 (CA 19-
9) was elevated to 60.9 U/mL. A follow-up abdominal
computed tomography (CT) confirmed a 7.5 cm sized gall-
bladder cancer with liver invasion (Fig. 2), consistent with
clinical Stage III cancer according to the TNM system
(tumor-node-metastasis classification system).
Cholecystectomy and segmental hepatectomy of seg-
ments S4b and S5 were performed. An 8 cm, friable gall-
bladder mass had grown outward and involved the liver
(Fig. 3). Pathologically, the tumor was a sarcomatoid car-
cinoma in Stage III (Fig. 4). The surgical margin was free of
vessel or cystic duct invasion. The tumor had an adeno-
carcinoma component with some glandular structures and
showed positive staining for cytokeratin (AE1/AE3) and a
sarcoma component with spindle cells staining positively
for vimentin.
The postoperative CA 19-9 level decreased to 28.5 U/
mL. Epigastric pain improved and the patient did not report
any other discomfort. However, 3 months later, the follow-
up abdominal CT revealed a peritoneal, poorly enhancing
soft tissue mass over the anterior of the liver and variably
sized nodules on the omentum (Fig. 5). A CT-guided biopsy
confirmed metastatic peritoneal sarcomatoid carcinoma.
The patient received chemotherapy consisting of three
courses of cisplatin (30 mg/m2) and fluorouracil (2600 mg/
m2). The patient died 6 months after diagnosis.
Discussion
We reported the case of a 52-year-old female patient who
presented with postprandial epigastric pain that had per-
sisted for 1 year. Peritoneal metastasis occurred 3 months
later, and the patient died 6 months after diagnosis. Theprognosis of gallbladder sarcomatoid carcinoma is poor
even after curative resection and there is as yet no known
effective adjuvant therapy.
The risk factors for gallbladder sarcomatoid carcinoma
are not clear. Risk factors for gallbladder carcinoma include
adenomyomatosis, anomalous union of the pan-
creaticobiliary ductal system, cholelithiasis, chronic Sal-
monella typhi infection, a first-degree relative with
gallbladder cancer, and exposure to carcinogens such as
methylcholanthrene, o-aminoazotoluene and nitrosamines.
Our patient did not have any of these risk factors. Patients
with gallbladder sarcomatoid carcinoma often present with
nonspecific symptoms and signs such as abdominal pain,
nausea, anorexia, fever, jaundice, weight loss, or a
palpable mass [1,6]. Varying CA 19-9 levels were noted
among previous gallbladder sarcomatoid carcinoma cases
[1,7]. Our patient was diagnosed at a late stage when she
presented with abdominal pain and had an elevated CA 19-9
level that decreased after radical resection.
Because gallbladder sarcomatoid carcinoma is poorly
understood, a definite staging system is not available. Most
case series or reports are staged by the TNM classification
of gallbladder carcinoma. The most important treatment is
surgical resection. Our patient underwent a radical resec-
tion; adjuvant chemotherapy or radiotherapy were not
used due to a lack of evidence supporting a therapeutic
benefit [6,8]. The use of fluorouracil plus oxaliplatin for
adjuvant therapy was previously documented in another
Figure 2 Abdominal computed tomography confirmed a
7.5 cm gallbladder cancer with liver invasion.
Figure 3 An 8 cm friable mass extending outward from the
gallbladder and involving the liver.
Figure 4 (A) Sarcomatoid carcinoma of the gallbladder.
Immunohistochemical staining showing (B) cytokeratin-positive
epithelial component; (C) vimentin-positive sarcomatous
component.
Gallbladder sarcomatoid carcinoma 63case report [7]. In that case, the patient was diagnosed
with Stage II disease and was still alive 6 months
postoperatively.
Our patient had a poorly enhanced, peritoneal soft tis-
sue mass over the anterior of the liver with differently sized
nodules on the omentum 3 months after surgery. We used a
regimen of fluorouracil plus cisplatin, similar to that usedpreviously, for palliative chemotherapy. Fluorouracil is
typically used for gallbladder carcinoma and oxaliplatin for
sarcoma. The overall median survival for sarcomatoid car-
cinoma ranged from 2 months to 9 months [1,3,9]. In one
meta-analysis, it was found that patients with a tumor >
5 cm have a significantly worse outcome as determined by
Figure 5 A metastatic peritoneal sarcomatoid carcinoma
identified by abdominal computed tomography.
64 M.-W. Wong et al.Kaplan-Meier survival analysis. The median survival was 11
months in patients with tumors < 5 cm but only 5 months in
patients with tumors > 5 cm. This observation may be
explained by the presence of a greater extent of local in-
vasion with larger tumors due to the thinness of the gall-
bladder wall. Age, sex, epithelial and mesenchymal
component types, and the presence of a gallstone did not
significantly influence prognosis [3]. Prognosis was poor
even with surgical resection with a median survival after
surgery of 7 months. For patients with advanced Stage III or
IV disease, the median survival after surgery was reduced
to 4 months. Furthermore, the median time to recurrence
was < 1 year and the median survival time was only 1.5
months after recurrence [6].
Our patient underwent radical resection of a Stage III,
8 cm gallbladder sarcomatoid carcinoma. The post-
operative performance status was good. However, recur-
rence without any symptoms was noted after 3 months and
the patient received 3 courses of chemotherapy (fluoro-
uracil plus cisplatin). The gallbladder cancer may have
spread directly or via lymphatic, vascular, neural,intraperitoneal, and intraductal pathways. Typical recur-
rence patterns include locoregional and distant spread [10].
Locoregional recurrence at sites such as the porta hepatis
of the resection margin or the retroperitoneum is due to
microscopic residual disease or lymphatic spread. However,
distant or intrahepatic metastasis is due to hematogenous
spread. Our patient had early peritoneal recurrence indic-
ative of distant metastasis and it is likely that microscopic
spread had already occurred. Because the tumor was >
5 cm (8 cm) and the disease was in late stage (Stage III) we
performed a radical resection with a free surgical margin.
In conclusion, surgical resection is the only proven
curative treatment for gallbladder sarcomatoid carcinoma
and early diagnosis is the key to a better prognosis. We
strongly suggest early imaging follow-up after radical
resection for patients with advanced gallbladder sarcoma-
toid carcinomas > 5 cm and/or Stage III or IV disease which
may be due to undetectable small metastases. Further
evidence of survival benefit for pathology-based, combined
adjuvant chemotherapy is needed as no adjuvant therapies
have proven effective thus far.Conflicts of interest
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